<DOC>
	<DOCNO>NCT01492621</DOCNO>
	<brief_summary>Subjects major depression evaluate intensively characterized questionnaire , computerize cognitive evaluation laboratory investigation . Magnetic resonance imaging use document baseline white matter structure . subject receive desvenlafaxine adjust clinically indicate . After 16 week evaluations repeat .</brief_summary>
	<brief_title>Effect Antidepressants White Matter Structure</brief_title>
	<detailed_description>40 subject include study . Diagnosis confirm MINI . Participants characterise use questionnaire , pain threshold , cognition , facial expression record MRI . Desvenlafaxine initiate 50mg AM . At week 8 Desvenlafaxine may increase 100mg clinically indicate . Measures repeat end study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Major depression Age 18 55 Hamilton grater equal 20 Major neurologic disorder Major cardiovascular disorder Unstable medical condition Significant psychiatric comorbidity Current substance dependance Pregnancy lactation Treatment resistance define nonresponse 2 antidepressant treatment ( adequate dose duration )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>major depression</keyword>
	<keyword>DTI</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>cognition</keyword>
</DOC>